GFAP and myeloid sarcoma: Additional applications include determining relapses in MS (miR-155/150 ± CD29/CD31) [130], sEV-associated GFAP as a circulating biomarker of TBI severity correlating with CT-positive lesions post-trauma (EV-GFAP + UCH-L1) [131], and molecular subtyping in frontotemporal dementia via sEV-TDP-43 and tau isoforms [89].